TrialDiabetes, obesity & metabolism2018

Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4-week, double-blind, randomized, placebo-controlled phase 2 trial.

Akira Shimada et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.